Skip to content

Can the value of the tumor biomarker CA-125 divided by the value of the tumor biomarker CEA help in the diagnosis of ovarian cancer in women with pelvic cancer?

Can CA-125/CEA ratio be used for the differential diagnosis between ovarian and non-ovarian cancers? A diagnostic cross-sectional retrospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN15248104
Enrollment
340
Registered
2024-02-16
Start date
2016-04-21
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer, other intra-abdominal neoplasms Cancer

Interventions

A diagnostic cross-sectional retrospective study is performed in patients with pelvic mass, peritoneal carcinomatosis and/or ascites and initial suspicion of ovarian malignancy. All patients have seru

Sponsors

Hospital de Câncer de Barretos
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Patients with a pelvic mass, peritoneal carcinomatosis and/or ascites

Exclusion criteria

Exclusion criteria: 1. Previous surgery at another service 2. If the pathology results showed benign lesions 3. If the sample was insufficient for a definitive diagnosis 4. If no biopsy was performed

Design outcomes

Primary

MeasureTime frame
Receiver operating characteristic (ROC) curves to determine the cut-off values for CA-125/CEA ratio in the participants, comparing ovarian cancer with non-ovarian cancer, gastrointestinal cancer, and colorectal cancer, followed by a performance characteristic test to determine sensitivity, specificity, positive predictive value, accuracy (all ovarian cancer positive cases divided by the participants), type I error, 1, and 2 (the power of the test), positive predictive value, negative predictive value, accuracy (all ovarian cancer positive cases divided by all participants), type I error, 1 minus type II error (the power of the test), positive and negative likelihood ratios with pathology findings as the gold standard (chi-squared test or Fisher's test). Measured at a single timepoint.

Secondary

MeasureTime frame
The same as the primary outcome measure but after propensity score matching analysis (PSM)

Countries

Brazil

Contacts

Public ContactJeferson Zanon
jeferson.zanon@hcancerjales.com.br+55 (0)17 3624 3900

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026